40 results about "Platinum Compound" patented technology

The invention belongs to the technical field of medicine synthesis, and particularly relates to a tetravalent platinum compound as well as a preparation method and application thereof. The invention provides a tetravalent platinum compound. The tetravalent platinum compound has a structure shown as a formula a to a formula d, wherein linker is respectively connected with a Pt-containing mother nucleus and a PARP inhibitor through-O-C = O; the PARP inhibitor comprises a carboxyl-containing structure and a carboxyl-free structure; when the PARP inhibitor contains a carboxyl structure, the linker is when the PARP inhibitor does not contain the carboxyl structure, and the data of the linker as the embodiment shows that the tetravalent platinum compound provided by the invention has good anti-tumor activity and low tumor drug resistance when being used as the PARP inhibitor.

The application discloses a phosphorescent dopant material of a platinum compound, a preparation method, an organic electroluminescent device and application, the phosphorescent dopant material is a platinum compound with a structure shown in chemical formula I, the compound introduces a bicyclic structure on the basis of a parent nucleus, a high conjugated electron distribution system, so that the electron distribution and the excited state can be controlled, and the stability of the material is enhanced. The organic electroluminescent device prepared by adopting the compound as a light-emitting layer dopant material has high luminous efficiency, long service life and the technical effect of improving the driving voltage.

To provide platinum compounds that can be useful as emitters in display and lighting applications.SOLUTION: Platinum compounds of Formulas I and II useful in a variety of devices, such as, for example organic-light emitting diodes (OLEDs).SELECTED DRAWING: Figure 1

The present invention provides a derivative having a desloratadine tetravalent platinum structure, a preparation method, and a use thereof. The compound having a desloratadine tetravalent platinum structure is shown in general formula (I), #imgabs0# wherein #imgabs1# is selected from cisplatin or oxaliplatin; L is hydroxyl or #imgabs2#. The desloratadine tetravalent platinum compound of the present invention has good anti-tumor proliferation activity and a good therapeutic effect on metastatic malignant tumors; it can effectively inhibit the tumor epithelial-mesenchymal transition (EMT) process and effectively activate tumor immune response, and can be used to prepare anti-tumor drugs, especially providing a new direction for the research and development of anti-metastatic malignant tumor drugs.

The invention relates to a method for producing trimethylplatinum(IV) iodide and trimethylplatinum(IV) iodide obtainable according to said method and the use thereof as a reactant for producing platinum(IV) compounds, as a precatalyst and as a catalyst. The platinum(IV) compounds thus obtainable, as well as the use thereof as precursors for the deposition of platinum layers and platinum-containing layers on a surface of a substrate are also the subject matter of the invention. The invention also relates to a substrate comprising a platinum layer or a platinum-containing layer on a surface, and to a method for producing an electronic component, in particular an electronic semiconductor component, or an electrode for a fuel cell using a platinum(IV) compound obtainable using trimethylplatinum(IV) iodide, which is obtainable by means of the method described herein.

The invention relates to a method for producing trimethylplatinum(IV) iodide and trimethylplatinum(IV) iodide obtainable according to said method and the use thereof as a reactant for producing platinum(IV) compounds, as a precatalyst and as a catalyst. The platinum(IV) compounds thus obtainable, as well as the use thereof as precursors for the deposition of platinum layers and platinum-containing layers on a surface of a substrate are also the subject matter of the invention. The invention also relates to a substrate comprising a platinum layer or a platinum-containing layer on a surface, and to a method for producing an electronic component, in particular an electronic semiconductor component, or an electrode for a fuel cell using a platinum(IV) compound obtainable using trimethylplatinum(IV) iodide, which is obtainable by means of the method described herein.

The invention relates to a pegylated cis-platinum compound as well as a preparation method and application thereof, and belongs to the technical field of drug carriers. The pegylated cis-platinum compound is obtained through covalent coupling of polyethylene glycol and cis-platinum. The invention provides a novel pegylated cis-platinum compound and a preparation method thereof, a pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the pharmaceutical composition, and particularly relates to a nucleic acid pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the nucleic acid pharmaceutical composition. The nucleic acid medicine composition preparation can deliver the nucleic acid medicine into cells, the transport rate of the nucleic acid medicine is increased, toxicity is reduced, and therefore the treatment effect of the nucleic acid medicine is improved.

To provide a drug-induced renal dysfunction relieving agent that enables inhibition or mitigation of renal dysfunction resulting from administration of a drug.SOLUTION: A drug-induced renal dysfunction relieving agent comprising, as an active ingredient, a dopamine D2-like receptor agonist. The dopamine D2-like receptor may be DRD2. The dopamine D2-like receptor agonist may be at least one selected from the group consisting of quinpirole, dopamine, ropinirole, and bromocriptine. The agent is preferably administered to a patient having drug-induced renal dysfunction caused by administration of a platinum-based anticancer agent, an antibacterial agent, an antiviral agent, a contrast medium, or an NSAIDs.SELECTED DRAWING: None

The invention provides a composite high-temperature insulating material as well as a preparation method and application thereof. The composite high-temperature insulating material comprises a silica gel composite material and a mica paper composite material; wherein the raw materials of the silica gel composite material comprise the following components in parts by weight: 100 parts of raw silicone rubber; 1-50 parts by weight of silicone resin; 0-15 parts by weight of a structured control agent; 1-60 parts by weight of a reinforcing system; 10-150 parts by weight of a main flame retardant system; 5-100 parts by weight of a synergistic flame retardant system; 5-150 parts by weight of an inorganic filling system; 0-300 parts by weight of an organic solvent; the synergistic auxiliary agent comprises 1-200ppm of a platinum compound or a complex based on the platinum content; 1-10 parts by weight of a curing agent system; 0-1 part by weight of a curing inhibitor system; and 0.1-10 parts by weight of a color matching system. In a special system, the silica gel composite material is compounded with the mica paper composite material by adopting a set process through the formula design of the silica gel composite material, so that the flame retardant property is excellent, and meanwhile, the requirements that the high-temperature sintering non-cracking shape is kept well and the crusting property is complete are met, so that the flame-retardant, fireproof and fire-resistant requirements are met.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotope variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof, and a pharmaceutical composition comprising same and a use thereof as a radiosensitizing drug.

A thermal conductive silicone composition including: (A) an organopolysiloxane having at least two alkenyl groups per molecule: 100 parts by mass; (B) an organohydrogen polysiloxane having at least two silicon atom-bonded hydrogen atoms per molecule: such that (the number of Si—H groups in component (B)) / (the number of alkenyl groups in component (A)) is 0.5 to 3.0; (C) a filler containing one or more thermal conductive powders: 800 to 20,000 parts by mass; (D) a hydrolyzable organopolysiloxane of formula (1): 20 to 400 parts by mass; (E) an organosilane of formula (2), R2bSi(OR3)4-b: 0.01 to 100 parts by mass; (F) platinum or a platinum compound: 0.1 to 500 ppm as platinum atoms relative to component (A); and (G) a reaction regulator: 0.01 to 1 parts by mass.

The invention discloses a polygonal anthracene functionalized BODIPY supramolecular metal ring compound as well as a preparation method and application thereof, and belongs to the technical field of supramolecular materials, the polygonal anthracene functionalized BODIPY supramolecular metal ring compound is obtained by self-assembly reaction of an anthracene functionalized BODIPY photosensitizer with a specific structure and a platinum compound; by selecting platinum compounds with different coordination included angles, triangular, quadrilateral and hexagonal supramolecular metal ring compounds are respectively prepared. Furthermore, amphiphilic polymer F127 is used for wrapping the supramolecular metal ring compound to form water-soluble nanoparticles, so that phototherapy and chemotherapy combined therapy of hypoxic tumors can be realized, and the amphiphilic polymer F127 has a wide application prospect in the aspects of biological imaging and tumor therapy.

The invention provides a 10-hydroxybenzoquinoline platinum complex as well as a synthesis method and application thereof, and belongs to the technical field of medicines, and the chemical formula of the 10-hydroxybenzoquinoline platinum complex is C15H15ClNO2 PtS. The platinum compound L-Pt shows a remarkable inhibition effect on MDA-MB-231 cancer cells, and the IC50 value of the platinum compound L-Pt is 0.092 + / -0.01 [mu] M and is far lower than that of a clinical anti-tumor drug cis-platinum (8.86 + / -0.79 [mu] M); compared with the prior art, synthesis raw material ligands L and cis-Pt (DMSO) 2Cl2 of the platinum compound L-Pt almost have no inhibition effect on MDA-MB-231 cancer cells, the platinum compound L-Pt has high tumor selectivity on the MDA-MB-231 cancer cells, the 10-hydroxybenzoquinoline platinum compound L-Pt shows excellent anti-tumor activity, the potential value of the 10-hydroxybenzoquinoline platinum compound L-Pt as medicine development is shown, and the application prospect is broad. And the compound is expected to become a candidate substance for preparing various anti-tumor drugs.

The application provides a trifunctional tetravalent platinum compound of captopril-aspirin ligand and a reference drug of a bifunctional tetravalent platinum compound of captopril; and develops a nanomedicine Tf-GEVs@Pt(IV) of the aspirin-captopril trifunctional tetravalent platinum compound loaded in grapefruit extracellular vesicles (GEVs). The Tf-GEVs@Pt(IV) is prepared from the trifunctional tetravalent platinum compound as an active ingredient, the carrier grapefruit extracellular vesicles (GEVs), the carrier DSPE-PEG and the transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs@Pt(IV) can release the active component trifunctional tetravalent platinum compound in vivo. In addition to causing DNA damage, the trifunctional tetravalent platinum compound as the active component of the nanomedicine can effectively regulate inflammatory, fibrotic and immunosuppressive TME. The nanomedicine has a significant anti-tumor ability and has excellent therapeutic effect on metastatic malignant tumors, and is expected to provide a new candidate drug for clinical treatment of tumors and provide a new direction for research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

The present invention discloses a class of platinum(II) compounds with targeting effects, their derivatives, preparation methods, pharmaceutical compositions and applications. The structure of this class of platinum(II) compounds is as follows: The derivatives of this class of platinum(II) compounds refer to isomers of the platinum(II) compounds or mixtures thereof. This class of platinum(II) compounds and their derivatives have active targeting effects, can specifically inhibit related protein kinases and cancer cells. At the same time, the chemical structure contains a C=N double bond, which can passively target tumors using the acidic microenvironment of tumors and reduce tissue toxicity. They exhibit the characteristics of high efficiency and low toxicity in anti-tumor, and can overcome the drug resistance problems of existing platinum-based and targeted drugs. In addition, the synthesis method of this class of platinum(II) compounds is simple and easy to implement.

The invention relates to the field of biological medicine, in particular to trans-platinum and a preparation method and application thereof. The invention provides trans-platinum. The trans-platinum has a structure as shown in a formula I, # imgabs0 # is shown as a formula I; wherein R1 to R5 are independently selected from hydrogen, halogen, CHO, OH, NH2 or CH3. The trans-platinum provided by the invention is a divalent platinum compound with pyroptosis induction capability, has a trans structure, and comprises two chlorine ligands at the trans position, an ammonia ligand at the trans position and a nitrogen-containing heterocyclic ring ligand at the trans position, and the nitrogen-containing heterocyclic ring ligand is designed to be pyridine or a derivative ligand thereof. Due to the existence of a trans structure and a planar ligand, a DNA cross-linking mode different from classical platinum drugs such as cis-platinum is adopted, and the compound has pyroptosis induction capacity, can induce tumor cell immunogenic death and activate anti-tumor immune response, and has a cancer cell killing mode different from that of cis-platinum and excellent cancer cell killing capacity as a platinum drug.

The present invention discloses a novel platinum compound represented by formula (I), and their use as a medicament, especially a medicament for treating cancer alone or in combination, and preventing cancer. Experiments have shown that the novel platinum compound of the present invention has a superior in vivo anti-tumor effect, which is significantly better than the clinical drug carboplatin; and the water solubility of the platinum drug is significantly improved, and it can be made into a lyophilized powder or an injection, solving the defect of inconvenient clinical use. In summary, the platinum compound disclosed in the present invention has a good prospect for clinical application.

This invention belongs to the field of silicone rubber technology and relates to a flame-retardant compounded silicone rubber and its preparation method. The invention involves first adding methyl vinyl silicone rubber raw material, precipitated silica, hydroxyl silicone oil, zinc stearate, silane coupling agent, and composite flame-retardant filler to a kneader for kneading. After kneading, heat treatment, and cooling, compound A is obtained. Then, compound A is mixed evenly with a platinum-containing flame-retardant additive in a specific ratio on a two-roll mill to obtain the flame-retardant compounded silicone rubber. The platinum-containing flame-retardant additive is a compound of platinum compound and vinyl amino silicone oil at a mass ratio of 1:0.5~1. This method is simple, and the prepared compounded silicone rubber has high flame-retardant properties. It utilizes a combination of platinum compound, nitrogen-containing organic compound, and composite flame-retardant filler, resulting in a strong synergistic flame-retardant effect. It also offers advantages such as good roller workability, high processing efficiency, and minimal yellowing of vulcanized samples, making it easy to promote and apply.

The invention discloses a high-thermal-conductivity flame-retardant organic silicon pouring sealant for a power battery module as well as a preparation method and application of the high-thermal-conductivity flame-retardant organic silicon pouring sealant. The pouring sealant is composed of a component A and a component B, wherein the component A contains vinyl-terminated polysiloxane, a composite heat-conducting filler, a synergistic flame retardant, a cross-linking agent and an inhibitor; and the component B contains vinyl-terminated polysiloxane, a composite heat-conducting filler, a synergistic flame retardant and a platinum catalyst. The composite heat-conducting filler is prepared from modified spherical aluminum oxide and flaky boron nitride according to a specific proportion, and the synergistic flame retardant is prepared by compounding encapsulated red phosphorus and a platinum compound. The component A and the component B are mixed according to the ratio of 1: 1 and then cured to form the elastomer with high thermal conductivity (greater than or equal to 2.0 W / m.K), high flame retardance (UL94 V-0), low stress and high reliability. The pouring sealant disclosed by the invention is particularly suitable for a power battery module needing efficient heat management and extreme safety.

The invention provides a glycyrrhetinic acid-platinum compound as shown in a structural formula as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: taking glycyrrhetinic acid as a raw material, coupling the glycyrrhetinic acid with dimethyl 3-amino-1, 1-cyclobutanedicarboxylate through an amido bond, converting the glycyrrhetinic acid into a sodium salt, and carrying out coordination substitution reaction on the sodium salt and a hydrate cis-[PtA2 (H2O) 2] (NO3) 2 of a platinum drug on the market to prepare a compound 1; the compound provided by the invention has inhibitory activity on human hepatoma cell lines HepG2, Huh7 and SK-Hep-1, can form a pharmaceutical composition with a pharmaceutically acceptable carrier, and can be used for preparing anti-hepatoma drugs.

The invention belongs to the technical field of synergistic extraction, and particularly relates to a method for synergistically and co-extracting platinum and iridium by using a composite extracting agent. According to the method, an amino-containing extraction agent and a phosphorus-containing extraction agent are innovatively compounded to obtain the synergistic extraction agent, and the volume ratio of the amino-containing extraction agent in an organic phase is controlled to be 1-62%, and the volume ratio of the phosphorus-containing extraction agent in the organic phase is controlled to be 1-62%. According to the method, two extractants are used for extracting platinum and iridium, so that the two extractants play a synergistic role to the greatest extent, then the synergistic extractant is used for extracting a solution containing platinum and iridium, finally, the platinum and the iridium are separated from the extractants through reverse extraction, and finally a mixture only containing a platinum compound and an iridium compound is obtained. The platinum and the iridium in the mixture can be subsequently separated according to needs. By adopting the method disclosed by the invention, platinum and iridium can be effectively recovered from a mixture of various substances, and the recovery rate of platinum and iridium is greater than 99.5%.

The invention belongs to the technical field of biological medicines, and discloses an oxaprozin coupled cis-platinum compound as well as a preparation method and application thereof. The oxaprozin coupled cis-platinum compound disclosed by the invention is tetravalent platinum prepared by coupling cis-platinum and oxaprozin which is a drug with carboxyl; the oxaprozin coupled cis-platinum compound disclosed by the invention can improve the toxic and side effects of cis-platinum and increase novel axial functional groups, and has the technical advantages of excellent anti-tumor activity, stability, safety and low cost.

The present invention discloses a tetravalent platinum complex containing APR-246, having a structure as shown in Formula I: wherein n is selected from 0, 1, 2, 3, or 4; R is selected from a branched or linear C1-C20 alkyl group; and R2 is selected from a branched or linear C1-C20 alkyl group. The tetravalent platinum compounds containing the p53 mutation activator APR-246 provided by the present invention can enhance the anti-tumor activity of APR-246 and leverage the anti-tumor advantages of APR-246 and divalent platinum drugs. By utilizing the unique anti-tumor mechanism of APR-246, they can work together with platinum drugs to achieve excellent synergistic anti-tumor efficacy, while also significantly helping to improve tumor drug resistance.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.

The invention provides a trifunctional tetravalent platinum compound of a captopril-aspirin ligand and a reference drug captopril difunctional tetravalent platinum compound of the trifunctional tetravalent platinum compound. The invention also develops a nano-drug Tf-GEVs (at) Pt (IV) of an aspirin-captopril three-function tetravalent platinum compound entrapped by grapefruit extracellular vesicles (GEVs). The Tf-GEVs (at) Pt (IV) is prepared from a trifunctional tetravalent platinum compound serving as an active component, grapefruit extracellular vesicles (GEVs) serving as a carrier, DSPE-PEG serving as a carrier, and a transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs (at) Pt (IV) can release an active component, namely a trifunctional tetravalent platinum compound in vivo. The trifunctional tetravalent platinum compound as a nano-drug active component can cause DNA damage, and can also effectively regulate inflammatory, fibrosis and immunosuppressive TME. The nano-drug is remarkable in anti-tumor capacity, has an excellent treatment effect on metastatic malignant tumors, is expected to provide a new candidate drug for clinical treatment of tumors, and provides a new direction for research and development of novel platinum drugs and anti-metastatic malignant tumor drugs.

We provide a silicone rubber that is biocompatible with the human body and can be manufactured at a lower cost than conventional methods. [Solution] The silicone admixture according to the present invention comprises a casting-type silicone rubber, a vulcanizing agent, and a silicone polymer without crosslinking sites, and can become a cured product with a loss tangent (Tanδ) of 0.2 or more at 10°C to 40°C. The casting-type silicone rubber is a liquid silicone rubber that can be cured by addition reaction, and the vulcanizing agent is a platinum compound. The silicone polymer without crosslinking sites is a dimethyl silicone polymer.

The present invention relates to a spiro-containing platinum compound and an organic light-emitting device compound. The structure of the spiro-containing platinum compound is as shown in formula (I). Provided is a platinum compound of a spiro-containing ONCN tetradentate ligand. The material can improve the heavy-atom effect of a phosphorescent material, thereby improving the energy utilization rate of singlet and triplet excitons in the light emitting process. The spiro rings in the platinum compound provide sufficient 3D spatial configuration, thereby reducing the aggregation effect, further improving the luminous efficiency of the material, and providing the possibility for further industrialization of the material. The platinum compound is applied to an organic light-emitting diode and results in high efficiency and good thermal stability, photophysical properties, and device life.

The invention discloses carrier-free nanoparticles for targeting tumor cells as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the amphiphilic photosensitive platinum compound disclosed by the invention, a nanoparticle TPAQu-Pt-HA NPs which is stable in structure and controllable in drug release behavior and has a tumor targeting capability is constructed under the condition of no excipient. The carrier-free nanoparticle TPAQu-Pt-coated HA NPs prepared by the invention realizes the single-molecule multi-target effect through three mechanisms: (1) inducing DNA (Deoxyribose Nucleic Acid) damage of a cell nucleus and mitochondria and dsDNA leakage of cytoplasm, and effectively activating a cGAS-STING pathway; 2) the AIE effect endows the gene with stronger ROS production capacity, which causes mitochondrial dysfunction, promotes formation of GSDMA-N membrane pores, and finally causes pyroptosis; and 3) PTT aggravates mitochondrial dysfunction, strengthens pyroptosis of cells, and amplifies activation of a cGAS-STING pathway and subsequent anti-tumor immune response.

The application discloses a fireproof and flame-retardant coating, which comprises, in parts by weight, 80-100 parts of organic silicon modified water-based polyurethane, 2-5 parts of zirconium phosphate-platinum catalyst, 5-10 parts of mica powder and 5-10 parts of silicon dioxide. The application further discloses a preparation method of the fireproof and flame-retardant coating. The fireproof and flame-retardant coating has the characteristics of low surface energy, fireproof and flame-retardant due to the low surface energy of organic silicon, the introduction of silicon into the polyurethane base material, the catalytic effect of ZrP-Pt, the catalytic characteristics of zirconium phosphate, the porcelain characteristics of platinum, the interlayer structure of zirconium phosphate, the solidification of platinum compounds, the introduction of phosphorus elements, the carbon change of organic matter into amorphous carbon, the formation of a carbon layer, the support of the mica powder, the maintenance of the integrity of the ceramic structure and the synergistic effect of the coating.